Compare Altria Group Inc (MO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs ResMed Inc. — how do they compare? Altria Group Inc trades at $73.25 (market cap $124.67B), while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: Altria Group Inc is far larger — about 4.3× ResMed Inc.'s market cap, and Altria Group Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.
| MO | RMD | |
|---|---|---|
Market Cap | $124.67B | $28.81B |
Sector | Consumer Staples | Health |
52-Week High | $74.66 | $293.73 |
52-Week Low | $54.72 | $182.82 |
Enterprise Value | $145.75B | $27.99B |
Dividend Yield | 5.68% | 1.21% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
